Guiling Li
Impact in
- Obstetrics and Gynecology top 10%
- Endometrial and Cervical Cancer Treatments
-
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 19
- Cancer Treatment and Pharmacology 3
- Cancer Immunotherapy and Biomarkers 3
- PARP inhibition in cancer therapy 3
-
- Wnt/β-catenin signaling in development and cancer 3
- Co-authors
- Yeshan Chen (4 shared papers)Gang Wu (3 shared papers)Linli Shi (2 shared papers)Shuangbing Xu (1 shared paper)Yang Qin (1 shared paper)Yulan Zeng (1 shared paper)Fen Qu (2 shared papers)Wenbin Tan (1 shared paper)
- Journals
- Journal of Clinical Oncology (13 papers)Gynecologic Oncology (2 papers)Clinical Cancer Research (1 paper)Infection and Drug Resistance (1 paper)Infection and Immunity (1 paper)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Guiling Li
42 papers receiving 371 citations
Peers
Comparison fields: 5 of 88
- Obstetrics and Gynecology 41
- Oncology 109
- Reproductive Medicine 32
- Cancer Research 57
- Internal Medicine 9
Countries citing papers authored by Guiling Li
This map shows the geographic impact of Guiling Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guiling Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guiling Li more than expected).
Fields of papers citing papers by Guiling Li
This network shows the impact of papers produced by Guiling Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guiling Li. The network helps show where Guiling Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Guiling Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 53 | |
| 2 | 2024 | 31 | |
| 3 | 2014 | 29 | |
| 4 | 2021 | 27 | |
| 5 | 2012 | 17 | |
| 6 | 2016 | 16 | |
| 7 | 2014 | 15 | |
| 8 | 2004 | 15 | |
| 9 | 2020 | 14 | |
| 10 | 2014 | 13 | |
| 11 | 2023 | 12 | |
| 12 | 2011 | 12 | |
| 13 | 2024 | 11 | |
| 14 | 2021 | 11 | |
| 15 | 2019 | 11 | |
| 16 | 2020 | 9 | |
| 17 | 2021 | 8 | |
| 18 | 2010 | 8 | |
| 19 | 2020 | 6 | |
| 20 | 2024 | 6 |
About Guiling Li
Guiling Li is a scholar working on Oncology, Molecular Biology, Epidemiology, Obstetrics and Gynecology and Reproductive Medicine, having authored 50 papers that have together received 377 indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (8 papers), Endometrial and Cervical Cancer Treatments (7 papers), Cancer Treatment and Pharmacology (3 papers), Wnt/β-catenin signaling in development and cancer (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cancer Genomics and Diagnostics (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and PARP inhibition in cancer therapy (3 papers). The work is most often cited by research in Obstetrics and Gynecology (41 citations), Oncology (109 citations), Reproductive Medicine (32 citations), Cancer Research (57 citations) and Internal Medicine (9 citations). Guiling Li has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Yeshan Chen, Gang Wu, Linli Shi, Shuangbing Xu, Yang Qin, Yulan Zeng, Fen Qu, Wenbin Tan, Vi Nguyen and Donghai Li. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Clinical Cancer Research, Infection and Drug Resistance and Infection and Immunity.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.